Literature DB >> 2405486

A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.

T J McQuade1, A G Tomasselli, L Liu, V Karacostas, B Moss, T K Sawyer, R L Heinrikson, W G Tarpley.   

Abstract

A synthetic peptidemimetic substrate of the human immunodeficiency virus 1 (HIV-1) protease with a nonhydrolyzable pseudodipeptidyl insert at the protease cleavage site was prepared. The peptide U-81749 inhibited recombinant HIV-1 protease in vitro (inhibition constant Ki of 70 nanomolar) and HIV-1 replication in human peripheral blood lymphocytes (inhibitory concentration IC50 of 0.1 to 1 micromolar). Moreover, 10 micromolar concentrations of U-81749 significantly inhibited proteolysis of the HIV-1 gag polyprotein (p55) to the mature viral structural proteins p24 and p17 in cells infected with a recombinant vaccinia virus expressing the HIV-1 gag-pol genes. The HIV-1 like particles released from inhibitor-treated cells contained almost exclusively p55 and other gag precursors, but not p24. Incubation of HIV-like particles recovered from drug-treated cultures in drug-free medium indicated that inhibition of p55 proteolysis was at least partially reversible, suggesting that U-81749 was present within the particles.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2405486     DOI: 10.1126/science.2405486

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  72 in total

1.  Isolation of peptide aptamers that inhibit intracellular processes.

Authors:  J H Blum; S L Dove; A Hochschild; J J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

Review 2.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

3.  Reversal by dithiothreitol treatment of the block in murine leukemia virus maturation induced by disulfide cross-linking.

Authors:  Stephen Campbell; Masamichi Oshima; Jane Mirro; Kunio Nagashima; Alan Rein
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

4.  X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor.

Authors:  A L Swain; M M Miller; J Green; D H Rich; J Schneider; S B Kent; A Wlodawer
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

5.  An Efficient Synthesis of Hydroxyethylene Dipeptide Isosteres: The Core Unit of Potent HIV-1 Protease Inhibitors.

Authors:  Arun K Ghosh; Sean P McKee; Wayne J Thompson
Journal:  J Org Chem       Date:  1991-11       Impact factor: 4.354

Review 6.  Targeting structural flexibility in HIV-1 protease inhibitor binding.

Authors:  Viktor Hornak; Carlos Simmerling
Journal:  Drug Discov Today       Date:  2006-12-20       Impact factor: 7.851

7.  p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.

Authors:  M Huang; J M Orenstein; M A Martin; E O Freed
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Characterization of human immunodeficiency virus type 1 Pr55gag membrane association in a cell-free system: requirement for a C-terminal domain.

Authors:  E J Platt; O K Haffar
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

9.  In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.

Authors:  S Kageyama; T Mimoto; Y Murakawa; M Nomizu; H Ford; T Shirasaka; S Gulnik; J Erickson; K Takada; H Hayashi
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

10.  In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor.

Authors:  M J Otto; C D Reid; S Garber; P Y Lam; H Scarnati; L T Bacheler; M M Rayner; D L Winslow
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.